|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||0.46|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.